Keyword: Yescarta (axicabtagene ciloleucel)
Gilead tapped new CEO Daniel O’Day in part because of his cancer expertise. But he’s not planning to lead the company’s oncology ramp-up alone.
Gilead CFO Robin Washington plans to retire next March, giving brand-new CEO Daniel O'Day his first C-suite slot to fill.
With Yescarta on the market and other CAR-Ts on their way, Gilead’s Kite Pharma planted the flag for another manufacturing site.
With Ranexa and Letairis copies ready to bite $1.2 billion off its top line, Gilead's cutting loose 150 salespeople who rep its cardiopulmonary drugs.
French biotech Cellectis is building facilities in Paris and the U.S. to produce allogeneic CAR-T treatments.
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.
With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that.
Gilead and Novartis are working to ramp up launches of their CAR-T drugs, and both companies are hoping longer-term data will help do the trick.
Gilead's third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren't convinced.